Thursday Seminar Series – Heinz Läubli

As part of the BCI’s Seminar Series, we are pleased to welcome Dr Heinz Läubli from the University of Basel (Switzerland) to present at the BCI on Thursday 16^th January. For more information about Dr Läubli’s research, please click here.

The seminar is entitled: ‘Cancer Immunotherapy by Manipulation of Tumor-Associated Glycosylation’.

• Impact of the cancer-associated glycosylation on immune suppression
• Enzymatic targeting of cancer-associated glycosylation
• Discussion of the sialoglycan/Siglec pathway as new target for cancer immunotherapy
• Glycan manipulation for cellular therapies

Heinz Läubli is a physician scientist with clinical training and a specialisation in medical oncology. He is a senior attending physician at the University Hospital in Basel and a head of the laboratory for cancer immunotherapy at the Department of Biomedicine. His research focuses on glycan changes in solid tumors and their influence on the anti-tumor immune response. He is employing genetic and enzymatic manipulation to modify glycans for improvement of cancer immunotherapy. He has initiated different early phase clinical trials including trials involving cellular immunotherapies.

The seminar will be held in the Lister and Young Seminar Room, 12:30-13:30.

If you would like to arrange to meet with Dr Läubli, please contact Oliver Pearce (o.pearce@qmul.ac.uk).